LSE:GSKPharmaceuticals
GSK’s Exdensur China Approval Adds New Dimension To Valuation Debate
GSK (LSE:GSK) has received Chinese regulatory approval for Exdensur to treat chronic rhinosinusitis with nasal polyps in adults.
Exdensur is described as the first ultra long acting biologic approved in China for this condition.
The therapy is indicated for patients who do not respond adequately to conventional treatments.
The approval follows positive Phase III trial results and provides a twice yearly treatment option.
For you as an investor, this approval adds another product to GSK’s...